Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHP647 Induction in Ulcerative Colitis
NCT03259334Phase 3Terminated
- Sponsor
- Takeda
- Start
- Feb 2018
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of ontamalimab in ulcerative colitis (UC), sponsored by Takeda. Started Feb 2018; status: terminated.
02
Drugs
ontamalimab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03259334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03259334.